A review of the literature on the economics of vaccination against TB

Expert Review of Vaccines

Volumn 11, Issue 3, 2012, Pages 303-317

  Tu, Hong Anh T ^a   Vu, Hoa D ^a   Rozenbaum, Mark H ^a   Woerdenbag, Herman J ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

BCG; cost effectiveness; miliary TB; tuberculous meningitis; vaccination

Indexed keywords

BCG VACCINE;

BCG VACCINATION; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; TUBERCULOUS MENINGITIS;

BCG VACCINE; COST-BENEFIT ANALYSIS; HUMANS; TUBERCULOSIS; VACCINATION;

EID: 84859094551     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.197     Document Type: Review

References (37)

1. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22(6), 1154-1158 (1993).
2. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO Press, Geneva (2009).
3. World Health Organization. Weekly epidemiological record. 4, 25-40 (2004).
4. Rahman M, Takahashi O, Goto M, Fukui T. BCG vaccination and tuberculosis in Japan. J. Epidemiol. 13(3), 127-135 (2003).
5. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517), 1173-1180 (2006). The paper highlights the importance of BCG universal vaccination for children in countries with high TB incidence.
6. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr. Opin. Immunol. 21(3), 331-338 (2009).
7. McShane H. Vaccine strategies against tuberculosis. Swiss. Med. Wkly 139(11-12), 156-160 (2009).
8. Smith R. Eradication of tuberculosis by 2050 impossible without new vaccine. BMJ 338, b1291 (2009).
9. Skeiky YA, Sadoff JC. Advances intuberculosis vaccine strategies. Nat. Rev. Microbiol. 4(6), 469-476 (2006).
10. Sun R, Skeiky YA, Izzo A et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; preclinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27(33), 4412-4423 (2009).
11. + T cells in adults. Am. J. Respir. Crit. Care Med. 181(12), 1407-1417 (2010).
12. Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106(33), 13980-13985 (2009). This paper highlights the epidemiological benefits of novel vaccines and other TB therapies.
13. Altes HK, Dijkstra F, Lugner A, Cobelens F, Wallinga J. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment. Epidemiology 20(4), 562-568 (2009). This paper highlighted the importance of using the BCG vaccine for selective vaccination in countries with low TB incidence.
14. Ambrosch F, Klima H, Wiedermann G. Cost-benefit analysis of BCG-vaccination in Austria. Dev. Biol. Stand. 43, 121-126 (1979).
15. Hersh AL, Tala-Heikkila M, Tala E, Tosteson AN, Fordham von RC. Acost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guerin in Finland. Int. J. Tuberc. Lung Dis. 7(1), 22-29 (2003). This paper highlighted the importance of using the BCG vaccine for selective vaccination in countries with low TB incidence.
16. Nettleman MD. Use of BCG vaccine in shelters for the homeless. A decision analysis. Chest 103(4), 1087-1090 (1993). This paper concluded that BCG vaccination would be cost effective, if it was given to people who were at high risk of TB exposure.
17. Nettleman MD, Geerdes H, Roy MC. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine. Arch. Intern. Med. 157(10), 1121-1127 (1997).
18. Pathania VS, Trnka L, Krejbich F, Dye C. A cost-benefit analysis of BCG revaccination in the Czech Republic. Vaccine 17(15-16), 1926-1935 (1999).
19. Rahman M, Sekimoto M, Takamatsu I et al. Economic evaluation of universal BCG vaccination of Japanese infants. Int. J. Epidemiol. 30, 380-385 (2001).
20. Rahman M, Sekimoto M, Hira K, Koyama H, Imanaka Y, Fukui T. Is Bacillus Calmette-Guerin revaccination necessary for Japanese children? Prev. Med. 35(1), 70-77 (2002). The paper highlighted that revaccination was not cost beneficial in countries with low TB incidence.
21. Stilwell JA. Benefits and costs of the schools' BCG vaccination programme. BMJ 1(6016), 1002-1004 (1976).
22. Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination. Tuber. Lung Dis. 74(4), 288-292 (1993).
23. Tseng CL, Oxlade O, Menzies D, Aspler A, Schwartzman K. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study. BMC Public Health 11, 55 (2011). This paper highlighted the potential benefits of future TB vaccines.
24. Bishai DM, Mercer D. Modeling the economic benefits of better TB vaccines. Int. J. Tuberc. Lung Dis. 5(11), 984-993 (2001). This paper highlighted the potential benefits of future TB vaccines.
25. Aoki M. Characteristics of tuberculosis in Japan compared with those in other developed countries. Kekkaku 68, 533-538 (1993).
26. Global tuberculosis programme and global programme on vaccines: statement on BCG revacciantion for the prevention of tuberculosis. Wkly Epidemiol. Rec. 70, 229-236 (1995).
27. Karonga Prevention Trial Group. Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348, 17-24 (1996).
28. Centers for Disease Control. Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the advisory committee for elimination of tuberculosis. MMWR Morb. Mortal. Wkly Rep. 37, 663-675 (1988).
29. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271(9), 698-702 (1994).
30. Fine PEM. BCG vacination against tuberculosis and leprosy. Br. Med. Bull. 44, 691-703 (1988).
31. Adam T, Baltussen R, Torres T et al. Making choices in health: WHO guide in cost-effectiveness analysis. World Health Organization (2003).
32. College voor zorgverzekeringen (CVZ). Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie (2006).
33. WHO. Immunization, Vaccines and Biologicals. Tuberculosis. www.who.int/immunization/topics/tuberculosis/en/ (Accessed 20 September 2011)
34. WHO. Initiative for Vaccine Research (IVR). Acute Respiratory Infections (update September 2009). www.who.int/vaccine-research/diseases/ari/en/index4. html (Accessed 20 September 2011)
35. Aeras Tuberculosis Vaccine Candidates. www.aeras.org/our-approach. vaccine-development
36. Stop TB Partnership. www.stoptb.org
37. International Union Against Tuberculosis and Lung Disease. www.theunion.org/index.php?option=com-flexicontent&view=items&id= 226&Itemid=31&lang=en (Accessed 20 September 2011)